Core Viewpoint - The article discusses the promising efficacy of CAR-T cell therapy in treating relapsed or refractory multiple myeloma, highlighting the transition from traditional autologous CAR-T to in vivo CAR-T approaches, which simplify the manufacturing process and reduce costs [2][3][4]. Group 1: In Vivo CAR-T Therapy - In vivo CAR-T therapy involves directly delivering CAR transgenes to endogenous T cells within the body, eliminating the need for complex manufacturing and storage processes associated with traditional CAR-T therapies [3][4]. - A clinical study published in The Lancet reported the first human trial data for in vivo CAR-T therapy targeting B-cell maturation antigen (BCMA) in multiple myeloma patients, demonstrating effective treatment in four patients [4][18]. Group 2: ESO-T01 Development - ESO-T01 is a novel lentiviral vector designed for in vivo T cell engineering, developed by EsoBiotec and Prigen, featuring a humanized single-domain antibody CAR targeting BCMA [6][9]. - The vector has been engineered to reduce immunogenicity and enhance specificity, including mutations to the VSVG protein and overexpression of CD47 to evade the immune system [6]. Group 3: Clinical Trial Results - The ongoing Phase 1 trial involved four adult patients with relapsed or refractory multiple myeloma, all of whom had previously shown disease progression despite multiple treatments [9][10]. - Initial dosing of ESO-T01 was set at 2.0×10^8 transduction units, with all patients experiencing acute inflammatory responses post-infusion, including fever and low blood pressure [11][13]. - By the end of the two-month follow-up, two patients achieved stringent complete responses, while the other two showed partial responses with tumor shrinkage [12][14]. Group 4: Safety and Efficacy Observations - The trial noted significant hematological toxicities, including neutropenia and thrombocytopenia, but most adverse effects resolved during follow-up [13]. - The presence of CAR-T cells was first detected in peripheral blood between days 4-8 post-infusion, peaking between days 10-17, indicating effective T cell expansion [14][18]. - The study provides valuable data for future research on in vivo CAR-T therapies, emphasizing the potential of ESO-T01 in treating difficult-to-manage multiple myeloma cases [19].

编辑丨王多鱼 排版丨水成文 电压门控钠 （ Na v ） 通道通过介导膜去极化时钠离子 （ Na + ） 的快速内流来控制神经元和肌肉的膜兴奋性。这些功能由核 心的 Na v 结构驱动，该结构由一 个中央孔道结构域 （PD） 和四个环绕的电压感受结构域 （VSD） 组成。 在人类的九种 Na v 亚型 （Na v 1.1 - 1.9） 中，由 SCN8A 基因编码的 Na v 1.6 在中枢神经系统中广泛表达，尤其在轴突远端起始段的密度极高，其功能紊乱 与 癫痫 等神经疾病密切相关。然而，Na v 1.6 虽然功能强大，但靶向药物极少，开发其精准、特异性强的新型分子一直是神经药理领域的一大挑战。 2025 年 7 月 4 日 ， 深圳医学科学院 颜宁 / 黄健 团队在 Cell Research 期刊发表了题为： Phrixotoxin-3 binds to three distinct antagonistic sites on human Na v 1.6 的研究论文。 该研究首次揭示了 蜘蛛毒素 Phrixotoxin-3 （PaurTx3） 通过三位点协同调控人源电压门控钠通道 Na v 1.6 ，为 ...

Core Viewpoint - The article discusses a promising strategy for inhibiting tumor metastasis by targeting tumor extracellular vesicles (TEV) through a newly developed lipidated nanophotosensitizer that can track and disable TEV, effectively suppressing both tumor growth and metastasis [2][4][8]. Group 1 - The research team from Southern Medical University has published a study in Nature Cancer, focusing on the concurrent inhibition of tumor growth and metastasis using a lipidated nanophotosensitizer [3]. - The developed lipidated nanophotosensitizer can efficiently track and destroy TEV, leading to a dual effect of inhibiting tumor growth and metastasis [4][8]. - The study utilized engineered palmitic acid surface-displaying nanoparticles that are effectively taken up by tumor cells and can actively track TEV, combining their distribution within tumor cells and TEV [6]. Group 2 - Upon near-infrared light exposure to the primary tumor site, reactive oxygen species (ROS) are generated both inside tumor cells and within TEV, resulting in photodynamic inhibition of the primary tumor and blocking intercellular communication by inhibiting TEV [6]. - The research demonstrated effective suppression of tumor growth and metastasis in various tumor models in female mice [6].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 在 急性 缺血性脑卒中 发生后 4.5 小时内， 静脉溶栓 仍是标准治疗方法。静脉溶栓后可能会发生血管再闭 塞，但在溶栓后的最初 24 小时内使用 抗血小板药物 或许可以预防这种情况。 替罗非班 （ Tirofiban） 是一种血小板糖蛋白 IIb-IIIa 受体拮抗剂，在实验模型中可减少大血管再闭塞。 2025 年 7 月 4 日，国际顶尖医学期刊《 新英格兰医学杂志 》 （NEJM） 发表了一项来自中国团队的 多 中心、双盲、随机对照试验 ASSET-IT 结果， 论文题为： Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke （ 静脉溶栓治疗卒中后早期使用替罗非班输注 ） 【1】 。 该研究纳入了 832 例非心源性 脑卒中 且在卒中 4.5 小时内接受 溶栓 治疗的患者，评估在溶栓后静脉输注 替罗非班 （ Tirofiban） 24 小时对卒中患者优良功能结局改善作用。 该研究由中国科学技术大学附属第一医院 （安徽省立医院） 胡伟 教授牵头，胡伟教授和洛杉矶大学 Jeffrey S ...

Core Insights - The article highlights significant research advancements published in the journal Cell, with a focus on studies led by Chinese scholars, covering topics such as organoid development, vascular dementia mechanisms, autoimmune disease treatments, and the role of synonymous mutations in cucumber domestication [2][4][8][12][17]. Group 1: Highly Vascularized Lung and Gut Organoids - A collaborative study from Cincinnati Children's Hospital and UCLA successfully constructed highly vascularized lung and gut organoids using human induced pluripotent stem cells (iPSCs), providing a platform for studying organ development and disease [4]. Group 2: Mechanisms of Vascular Dementia Repair - Research from UCLA identified key signaling pathways involved in brain repair for vascular dementia, specifically the CD39-A3AR pathway, and demonstrated that the A3AR agonist Piclidenoson could promote brain tissue repair and restore memory and gait functions [8]. Group 3: LAG-3/TCR Dual Antibody for Autoimmune Diseases - A study from NYU and Chinese institutions revealed a novel mechanism of LAG-3 receptor activation, which could lead to the development of dual-specific T cell inhibitory antibodies targeting LAG-3 and TCR, offering new therapeutic avenues for autoimmune diseases [12][13]. Group 4: Synonymous Mutations in Cucumber Domestication - Research from the Chinese Academy of Agricultural Sciences demonstrated that synonymous mutations can regulate important traits in cucumber domestication through epitranscriptomic mechanisms, challenging traditional views and suggesting new strategies for crop improvement [17].

Core Viewpoint - Ferroelectric materials are crucial for various electromechanical devices due to their excellent piezoelectric properties, enabling efficient conversion between electrical and mechanical energy [2][3][5]. Group 1: Development and Applications - Over the past century, a variety of ferroelectric materials have been developed, including lead zirconate titanate ceramics, lead-free ceramics, aluminum nitride films, and ferroelectric polymers based on polyvinylidene fluoride [2]. - These innovations have expanded the range of applications for ferroelectric materials and provided greater flexibility in device design, benefiting numerous piezoelectric devices such as cooling fans in smartphones and ultrasound transducers [2][5]. - The review paper published by Professor Li Fei highlights the reliance of small electromechanical devices, like speakers and motors in smartphones, on ferroelectric materials, which deform under an electric field [3]. Group 2: Research Progress and Future Directions - Recent research has focused on enhancing the piezoelectric performance of ferroelectric materials, proposing strategies to meet the growing demand for high-performance piezoelectric devices and systems [6]. - The review also emphasizes the need to consider the environmental impact of ferroelectric materials throughout their lifecycle, from raw material acquisition to manufacturing, usage, and disposal [6]. Group 3: Market Relevance - The current and emerging piezoelectric devices in the 3C (computer, communication, and consumer electronics) sector illustrate the diversity of piezoelectric applications, particularly in consumer electronics like smartphones [8].

Core Viewpoint - The establishment of a protein drug design research group at Shenzhen Medical Academy by Dr. Yang Wei, focusing on innovative protein-protein interaction design methods for cancer immunotherapy [2][3]. Group 1: Research Background - Dr. Yang Wei obtained his Ph.D. in Biology from Tsinghua University in 2019 and has conducted postdoctoral research at the University of Washington, collaborating with notable figures in protein design [2]. - His research emphasizes the development of new computational design methods for protein interactions, particularly in the context of immune regulation and cancer immunotherapy [2][3]. Group 2: Research Objectives - The protein drug design group aims to create new drug design methods and validation platforms to support the development of novel protein drugs [3]. - The group will focus on designing highly selective biomolecules for cancer immunotherapy, enhancing targeting while reducing systemic toxicity [3]. Group 3: Recent Research Publication - On February 26, 2025, Dr. Yang published a paper in Nature Communications titled "Design of high-affinity binders to immune modulating receptors for cancer immunotherapy," detailing his research direction [5]. - The study highlights the importance of immune receptors in maintaining internal balance and their role in cancer immunotherapy, which has significantly improved patient survival rates [9]. Group 4: Targeted Protein Design - The research team is developing a specialized 5-helix concave scaffold (5HCS) to create high-affinity protein binders targeting key immune receptors involved in cancer therapy, such as TGFβRII, CTLA-4, and PD-L1 [10][11]. - The designed protein binders have shown low nanomolar to picomolar affinity and strong biological activity, indicating their potential for therapeutic applications [11].

Core Viewpoint - The emergence of large language models (LLMs) like ChatGPT has significantly transformed academic writing, particularly in the biomedical field, raising concerns about research integrity and the accuracy of generated content [2][5]. Group 1: Impact of LLMs on Academic Writing - A study published in July 2025 revealed that approximately 200,000 out of 1.5 million biomedical papers indexed by PubMed in 2024 showed signs of LLM-generated text, accounting for about 1/7 of the abstracts [3][4]. - The use of LLM-assisted writing in biomedical publications is accelerating, with an earlier assessment indicating that about 1/9 of abstracts in the first half of 2024 exhibited similar signs [4]. - The study found that at least 13.5% of abstracts in 2024 were processed using LLMs, with some sub-corpora reaching as high as 40%, indicating a profound impact on scientific writing [5][10]. Group 2: Methodology and Findings - Researchers analyzed over 15 million abstracts from PubMed between 2010 and 2024, identifying 454 words that appeared significantly more frequently in 2024 compared to previous years, many of which were stylistic rather than content-related [7][9]. - The study highlighted that the vocabulary changes were more pronounced following the rise of LLMs than during significant events like the COVID-19 pandemic, with a notable increase in the use of adjectives and verbs [9][10]. - The proportion of LLM-assisted writing varies across disciplines, countries, and journals, with over 20% of abstracts in certain regions and fields utilizing LLMs [10]. Group 3: Challenges and Adaptations - Previous attempts to assess the impact of LLMs on academic writing faced challenges due to the lack of disclosure from users, making it difficult to evaluate the true extent of LLM usage [6]. - As authors become aware of specific vocabulary associated with AI-generated text, such as "delves," its usage may decline, complicating the assessment of AI's influence on academic writing [12]. - While using AI for text refinement or translation is deemed reasonable, generating large volumes of text without oversight raises concerns regarding research integrity [13].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 肺癌 是全球癌症相关死亡的首要原因。对于能够检测特定基因突变以实现靶向治疗且经济实惠、无创的方法的需求，以及预测患者生存结果的需求，凸显了提升 诊断和预后能力的重要性。当前的肺癌诊断模型常常无法整合多样化的患者数据，导致临床评估不全面。 2025 年 7 月 2 日， 温州医科大学附属第一医院 黄晓颖 教授、 北京大学未来技术学院 王劲卓 、温州医科大学 张康 、四川大学华西医院 王成弟 等，在 Cell 子刊 Cell Reports Medicine 上发表了题为 ： AI-enabled molecular phenotyping and prognostic predictions in lung cancer through multimodal clinical information integration 的研究论文。 该研究开发了一款多模态 集成 AI 模型 —— LUCID ， 通过多模态临床信息整合，实现了肺癌分子表型分析及预后预测。 除了突变识别之外，准确的生存时间预测仍是优化肺癌治疗策略的关键组成部分。这种预后信息使临床医生能够制定更个性化的治 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 播散性肿瘤细胞 （ Disseminated tumor cell，DTC） 可在远端器官中多年处于非增殖性的休眠状态，其 重新激活以及发生转移性定植的外源性诱因，目前尚不清楚。 2025 年 7 月 3 日，中国科学院上海营养与健康研究所 胡国宏 团队在 Cancer Cell 期刊发表了题为： Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps 的研 究论文。 该研究建立了 休眠肿瘤细胞谱系追踪系统 —— DormTracer ， 首次证实了休眠的播散性肿瘤细胞可苏醒 导致转移，并发现化疗激活休眠肿瘤细胞导致复发的作用及机制 ，这一发现解释了临床上观察到的乳腺癌 患者接受化疗获得初始疗效后往往难以避免后续发生转移复发的现象。 此外，该研究还提出了新型联合治疗策略—— S enolytic + 化疗 ，可抑制休眠的播散性肿瘤细胞在化疗后 的苏醒，为抑制肿瘤转移性复发提供了新方案。 该研究的亮点： 开发了一种基于重组酶的系统用于休眠肿瘤细 ...